Seminoma vs Non-Seminoma
Seminoma and non-seminoma are the two broad treatment categories of testicular germ-cell cancer. Seminoma consists of seminoma cells only. Non-seminoma includes embryonal carcinoma, yolk-sac tumour, choriocarcinoma, teratoma or mixed germ-cell tumours. The distinction matters because tumour-marker patterns, patterns of spread and post-treatment decisions differ. Mixed tumours are treated as non-seminoma. Importantly, a tumour that looks like seminoma under the microscope but has a genuinely elevated AFP is managed as non-seminomatous germ-cell cancer because pure seminoma does not produce AFP.
At a glance
| Feature | Seminoma | Non-seminoma |
|---|---|---|
| Typical age | Often slightly older than non-seminoma | Often younger adults |
| AFP | Should not be elevated in pure seminoma | May be elevated |
| Radiation sensitivity | More radiosensitive | Radiotherapy is not a standard systemic strategy |
| Treatment pattern | Surveillance/selected adjuvant therapy in stage I; cisplatin chemotherapy when advanced | Surveillance or adjuvant options in stage I; cisplatin chemotherapy when indicated; residual-mass surgery can be important |
What seminoma means
Seminoma often has a predictable pattern of lymphatic spread and is highly sensitive to cisplatin-based chemotherapy. Stage I seminoma is commonly managed with surveillance after orchidectomy; adjuvant carboplatin may be considered in selected situations. Radiotherapy has a limited modern role because of long-term toxicity and availability of effective alternatives.
What non-seminoma means
Non-seminomatous germ-cell tumours are biologically diverse. Tumour markers are more often elevated. Treatment depends on stage and IGCCCG risk group. After chemotherapy, residual masses may contain teratoma or viable cancer and can require surgical resection in selected patients.
Do they have different cure rates?
Both categories are highly curable, especially in early-stage disease. Prognosis in metastatic disease is refined using recognised risk classifications based on site of the primary tumour, metastatic sites and marker levels rather than the label alone.
Why pathology and markers must be read together
The orchidectomy report may describe multiple components and percentages. AFP, beta-hCG and LDH before and after surgery add information. A single word in the pathology report should not be interpreted without the stage, markers and imaging.
How tumour markers differ between the two groups
AFP is particularly useful because pure seminoma should not produce AFP; a convincing AFP elevation therefore changes the treatment category even if the microscope appearance looks seminomatous. Beta-hCG can rise in either seminoma or non-seminoma, while LDH is less specific and mainly reflects tumour burden. Marker values before and after orchidectomy also contribute to staging and, in metastatic disease, to prognostic grouping.
Fertility and survivorship
Fertility issues can occur in either type because the underlying testicular condition and cancer treatment can affect sperm. Sperm banking should be discussed before gonadotoxic therapy when future fertility matters.
What happens after orchidectomy in stage I disease?
For many men with stage I seminoma or non-seminoma, orchidectomy is the only immediate treatment and surveillance is preferred when follow-up can be performed reliably. Adjuvant treatment is considered selectively according to tumour type, pathological risk features and patient preference. The practical difference is that the surveillance schedules and relapse patterns are not identical, so the words “seminoma” and “non-seminoma” continue to matter even when the CT scan shows no spread.
Why the distinction changes treatment
Seminoma is highly sensitive to radiotherapy and cisplatin-based chemotherapy and has its own stage-specific pathways. Non-seminoma may contain embryonal carcinoma, yolk-sac tumour, choriocarcinoma or teratoma; residual teratoma after chemotherapy may require surgery because teratoma does not reliably respond to chemotherapy.
AFP is a diagnostic clue
A clearly elevated AFP is incompatible with pure seminoma. If pathology appears to show seminoma but AFP is elevated without another explanation, the case is generally managed as non-seminomatous germ-cell tumour. This is a practical example of why pathology and markers must be interpreted together.
Mixed germ-cell tumours are treated as non-seminoma
A tumour containing both seminoma and any non-seminomatous component follows non-seminoma treatment principles. The report should therefore list the components rather than simply calling the tumour “mixed.”
When to seek earlier medical review
Ask for review if pathology terminology is unclear, AFP is elevated despite a reported pure seminoma, or post-orchidectomy markers do not fall as expected. Those discrepancies can change treatment and deserve reconciliation before therapy starts.
Emergency warning signs
- Sudden severe testicular pain, especially with nausea (torsion must be excluded urgently)
- Rapidly increasing scrotal swelling or severe pain
- Breathing difficulty, severe headache or neurological symptoms in a patient with known advanced cancer
- Fever or worsening wound redness after surgery
What to bring to your consultation
- Complete orchidectomy HPE report
- Pre- and post-orchidectomy markers
- CT staging scans
- Any pathology review/slides if diagnosis is discordant
Questions to ask your doctor
- Does my pathology contain any non-seminomatous component?
- Is AFP elevated despite a seminoma label?
- How does this histology change management of any residual mass?
FAQs
Can seminoma contain teratoma?
A tumour with a non-seminomatous component such as teratoma is classified and treated as non-seminoma, not pure seminoma.
Is non-seminoma always more dangerous?
Not in a simple yes/no sense. Stage and prognostic group are more useful for estimating risk and selecting treatment.
Why does AFP change the diagnosis?
Pure seminoma should not secrete AFP. A confirmed AFP elevation suggests a non-seminomatous component or another cause.
Do both types need orchidectomy?
Yes, radical inguinal orchidectomy is the standard initial local treatment for most suspected testicular germ-cell cancers.
Related reading
- Testicular Cancer: Symptoms and Treatment
- Painless Testicular Lump: When to Worry
- Tumor Markers AFP, Beta-hCG and LDH Explained
- Radical Orchidectomy Explained
- Testicular Cancer and Fertility
- Urologist in Latur
References
- European Association of Urology (EAU). Testicular Cancer Guidelines, 2026. Diagnostic Evaluation https://uroweb.org/guidelines/testicular-cancer/chapter/diagnostic-evaluation
- European Association of Urology (EAU). Testicular Cancer Guidelines, 2026. Disease Management https://uroweb.org/guidelines/testicular-cancer/chapter/disease-management
- European Association of Urology (EAU). Testicular Cancer Guidelines, 2026. Follow-up After Curative Therapy https://uroweb.org/guidelines/testicular-cancer/chapter/followup-after-curative-therapy
- National Cancer Institute. Testicular Cancer Treatment (PDQ) – Patient Version https://www.cancer.gov/types/testicular/patient/testicular-treatment-pdq